Phenaceturic Acid

Phenaceturic Acid

SCHEMBL196523

O=C(O)CNC(=O)Cc1ccccc1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.62
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
GAA P10253 2/20 0.59
HPGD P15428 2/20 0.59
CRHBP P24387 1/20 0.58
CRHR2 Q13324 1/20 0.58
AKR1B1 P15121 1/20 0.58
ALDH1A1 P00352 5/20 0.58
LMNA P02545 2/20 0.58
EPHX2 P34913 1/20 0.57
MAPT P10636 2/20 0.56
RAB9A P51151 1/20 0.56
CNR1 P21554 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
TRPV1 Q8NER1 1/20 0.56
PKM P14618 1/20 0.55
KCNH2 Q12809 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenaceturic Acid SCHEMBL14126285 1.00 ATM (0.62) ATMKMT2AMEN1HDAC8HDAC6
SCHEMBL11288698 0.96 ATM (0.59) ATMKMT2AMEN1HDAC8HDAC6
Phenaceturic Acid SCHEMBL28124919 0.93 ATM (0.56) ATMKMT2AMEN1HDAC8HDAC6
SCHEMBL1454495 0.85 MEN1 (0.63) ATMKMT2AMEN1HDAC8HDAC6
SCHEMBL7769258 0.84 KMT2A (0.57) ATMKMT2AMEN1HDAC8HDAC6
SCHEMBL21398985 0.84 KMT2A (0.57) ATMKMT2AMEN1HDAC8HDAC6
SCHEMBL5102819 0.84 KMT2A (0.57) ATMKMT2AMEN1HDAC8HDAC6
SCHEMBL935646 0.84 CA2 (0.61) ATMALDH1A1LMNARAB9AL3MBTL1
SCHEMBL7769256 0.84 KMT2A (0.57) ATMKMT2AMEN1HDAC8HDAC6
Phenaceturic Acid SCHEMBL20912457 0.84 SLC7A5 (0.65) ATMKMT2AMEN1HPGDCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MARVELBIOME INC (US) 2026-04-02 US claimed
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH UNIV CALIFORNIA (US) 2026-03-19 US claimed
EP-4587116-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2025-07-23 EP claimed
WO-2025133394-A1 METABOLIC FINGERPRINTING OF SALIVA SAMPLES USING NMR MAVEN HEALTH GMBH (CH) 2025-06-26 WO claimed
US-12292445-B2 Methods of selecting subjects for treatment with metabolomic modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-05-06 US claimed
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 WO claimed
WO-2025054048-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS MarvelBiome, Inc. (US) 2025-03-13 WO claimed
CN-119125369-A Method for extracting and separating 5 nonsteroidal accompanying components in natural source conjugated estrogens 特丰制药有限公司 2024-12-13 CN claimed
CN-119044503-A Phenylacetylglycine as biomarker for microglial activation and application thereof 中国农业大学 2024-11-29 CN claimed
WO-2024243289-A2 GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2024-11-28 WO claimed
WO-2008097491-A2 BIOMARKERS OF IONIZING RADIATION RESPONSE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-08-14 WO claimed
US-20080187952-A1 Biomarkers of Ionizing Radiation Response WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-08-07 US claimed
US-7399638-B2 Prediction method for lipidosis TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-15 US claimed
US-20070166829-A1 Prediction method for lipidosis TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-19 US claimed
EP-1710585-A1 METHOD OF PREDICTING ABNORMALITY OF LIPID METABOLISM Takeda Pharmaceutical Company Limited (JP) 2006-10-11 EP claimed
EP-1047391-A4 ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS GILLETTE CO (US) 2005-01-19 EP claimed
US-6238655-B1 USEFUL IN THE FORMULATION OF DEODORANTS, ANTIPERSPIRANTS, BODY SPRAYS, AND OTHER SKIN TREATMENT COMPOSITIONS. THE GILLETTE COMPANY 2001-05-29 US claimed
EP-1047391-A1 ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS THE GILLETTE COMPANY (US) 2000-11-02 EP claimed
WO-1999030679-A1 α-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS THE GILLETTE COMPANY (US) 1999-06-24 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES IAPP, GPR119, FAHD1 ATM 1093/4885KMT2A 2945/4885MEN1 361/4885
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH IDO1, INMT, IDO2 ATM 3069/4885KMT2A 650/4885MEN1 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.